Invivyd (NASDAQ:IVVD) CFO Sells $16,896.51 in Stock

Key Points

• William Duke, CFO of Invivyd, sold 29,643 shares at an average price of $0.57, totaling approximately $16,896.51, significantly reducing his ownership by 37.53%.
• Invivyd reported a loss of $0.12 EPS for the last quarter, missing expectations, and generated revenue of only $11.79 million against analyst estimates of $23.16 million.
• Despite recent struggles, analysts maintain a buy rating on Invivyd, with an average target price set at $3.85, showing confidence in the company's future potential.

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) CFO William Duke sold 29,643 shares of Invivyd stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $0.57, for a total transaction of $16,896.51. Following the completion of the transaction, the chief financial officer directly owned 49,344 shares in the company, valued at $28,126.08. This represents a 37.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Invivyd Stock Performance

IVVD stock traded down $0.0101 during trading on Tuesday, reaching $0.5710. The company had a trading volume of 1,690,635 shares, compared to its average volume of 850,421. The company has a market cap of $68.60 million, a price-to-earnings ratio of -0.62 and a beta of 0.51. Invivyd, Inc. has a twelve month low of $0.3546 and a twelve month high of $2.74. The firm has a 50-day simple moving average of $0.75 and a 200-day simple moving average of $0.84.

Invivyd (NASDAQ:IVVD - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.08). Invivyd had a negative return on equity of 177.89% and a negative net margin of 238.33%.The firm had revenue of $11.79 million for the quarter, compared to analyst estimates of $23.16 million. Sell-side analysts expect that Invivyd, Inc. will post -1.64 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. HC Wainwright reiterated a "buy" rating and issued a $5.00 price objective on shares of Invivyd in a research note on Thursday, June 26th. D. Boral Capital cut their price target on Invivyd from $9.00 to $3.00 and set a "buy" rating on the stock in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating and three have given a Buy rating to the company's stock. According to MarketBeat, Invivyd currently has an average rating of "Buy" and an average target price of $3.85.

Institutional Trading of Invivyd

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Catalyst Funds Management Pty Ltd purchased a new position in Invivyd in the second quarter valued at $27,000. Vanguard Personalized Indexing Management LLC grew its position in shares of Invivyd by 238.6% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company's stock valued at $29,000 after acquiring an additional 28,146 shares during the period. Nuveen LLC purchased a new position in shares of Invivyd in the 1st quarter valued at about $65,000. Invesco Ltd. raised its holdings in Invivyd by 190.6% in the 1st quarter. Invesco Ltd. now owns 108,999 shares of the company's stock worth $66,000 after purchasing an additional 71,485 shares during the period. Finally, XTX Topco Ltd acquired a new position in Invivyd in the 1st quarter worth about $66,000. Institutional investors and hedge funds own 70.36% of the company's stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.